|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anglim PP, Alonzo TA and Laird-Offringa
IA: DNA methylation-based biomarkers for early detection of
non-small cell lung cancer: An update. Mol Cancer. 7:812008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo S, Yan F, Xu J, Bao Y, Zhu J, Wang X,
Wu J, Li Y, Pu W, Liu Y, et al: Identification and validation of
the methylation biomarkers of non-small cell lung cancer (NSCLC).
Clin Epigenetics. 7:32015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sardi AH and Islam S: Early lung cancer
detection, mucosal, and alveolar imaging. Curr Opin Pulm Med.
22:271–280. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang IV and Schwartz DA: Epigenetic
control of gene expression in the lung. Am J Respir Crit Care Med.
183:1295–1301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Belinsky SA: Gene-promoter
hypermethylation as a biomarker in lung cancer. Nat Rev Cancer.
4:707–717. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ooki A, Maleki Z, Tsay JJ, Goparaju C,
Brait M, Turaga N, Nam HS, Rom WN, Pass HI, Sidransky D, et al: A
panel of novel detection and prognostic methylated DNA markers in
primary non-small cell lung cancer and serum DNA. Clin Cancer Res.
23:7141–7152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Walter K, Holcomb T, Januario T, Yauch RL,
Du P, Bourgon R, Seshagiri S, Amler LC, Hampton GM and S Shames D:
Discovery and development of DNA methylation-based biomarkers for
lung cancer. Epigenomics. 6:59–72. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bedford MT and van Helden PD:
Hypomethylation of DNA in pathological conditions of the human
prostate. Cancer Res. 47:5274–5276. 1987.PubMed/NCBI
|
|
11
|
Portela A, Liz J, Nogales V, Setién F,
Villanueva A and Esteller M: DNA methylation determines nucleosome
occupancy in the 5′-CpG islands of tumor suppressor genes.
Oncogene. 32:5421–5428. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hao X, Luo H, Krawczyk M, Wei W, Wang W,
Wang J, Flagg K, Hou J, Zhang H, Yi S, et al: DNA methylation
markers for diagnosis and prognosis of common cancers. Proc Natl
Acad Sci USA. 114:7414–7419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Read ML, Seed RI, Fong JC, Modasia B, Ryan
GA, Watkins RJ, Gagliano T, Smith VE, Stratford AL, Kwan PK, et al:
The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in
thyroid cells. Endocrinology. 155:1222–1234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Imruetaicharoenchoke W, Fletcher A, Lu W,
Watkins RJ, Modasia B, Poole VL, Nieto HR, Thompson RJ, Boelaert K,
Read ML, et al: Functional consequences of the first reported
mutations of the proto-oncogene PTTG1IP/PBF. Endocr Relat Cancer.
24:459–474. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stratford AL, Boelaert K, Tannahill LA,
Kim DS, Warfield A, Eggo MC, Gittoes NJ, Young LS, Franklyn JA and
McCabe CJ: Pituitary tumor transforming gene binding factor: A
novel transforming gene in thyroid tumorigenesis. J Clin Endocrinol
Metab. 90:4341–4349. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Watkins RJ, Read ML, Smith VE, Sharma N,
Reynolds GM, Buckley L, Doig C, Campbell MJ, Lewy G, Eggo MC, et
al: Pituitary tumor transforming gene binding factor: A new gene in
breast cancer. Cancer Res. 70:3739–3749. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Read ML, Seed RI, Modasia B, Kwan PP,
Sharma N, Smith VE, Watkins RJ, Bansal S, Gagliano T, Stratford AL,
et al: The proto-oncogene PBF binds p53 and is associated with
prognostic features in colorectal cancer. Mol Carcinog. 55:15–26.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li C, Wang Y, Wang S, Wu B, Hao J, Fan H,
Ju Y, Ding Y, Chen L, Chu X, et al: Hepatitis B virus mRNA-mediated
miR-122 inhibition upregulates PTTG1-binding protein, which
promotes hepatocellular carcinoma tumor growth and cell invasion. J
Virol. 87:2193–2205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gu H, Bock C, Boyle P, Gnirke A and
Meissner A: Preparation of reduced representation bisulfite
sequencing libraries for genome-scale DNA methylation profiling.
Nat Protoc. 6:468–481. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Akalin A, Kormaksson M, Li S,
Garrett-Bakelman FE, Figueroa ME, Melnick A and Mason CE:
methylKit: A comprehensive R package for the analysis of
genome-wide DNA methylation profiles. Genome Biol. 13:R872012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
R Core Team, . R: A language and
environment for statistical. computing. R Foundation for
Statistical Computing; Vienna, Austria: 2013
|
|
25
|
Hsueh C, Lin JD, Chang YS, Hsueh S, Chao
TC, Yu JS, Jung SM, Tseng NM, Sun JH, Kuo SY and Ueng SH:
Prognostic significance of pituitary tumour-transforming
gene-binding factor (PBF) expression in papillary thyroid
carcinoma. Clin Endocrinol (Oxf). 78:303–309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
National Lung Screening Trial Research
Team, ; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD,
Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD:
Reduced lung-cancer mortality with low-dose computed tomographic
screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tammemägi MC, Katki HA, Hocking WG, Church
TR, Caporaso N, Kvale PA, Chaturvedi AK, Silvestri GA, Riley TL,
Commins J and Berg CD: Selection criteria for lung-cancer
screening. N Engl J Med. 368:728–736. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Brock MV, Hooker CM, Ota-Machida E, Han Y,
Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G,
et al: DNA methylation markers and early recurrence in stage I lung
cancer. N Engl J Med. 358:1118–1128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Leng S, Do K, Yingling CM, Picchi MA, Wolf
HJ, Kennedy TC, Feser WJ, Baron AE, Franklin WA, Brock MV, et al:
Defining a gene promoter methylation signature in sputum for lung
cancer risk assessment. Clin Cancer Res. 18:3387–3395. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sandoval J, Mendez-Gonzalez J, Nadal E,
Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A,
et al: A prognostic DNA methylation signature for stage I
non-small-cell lung cancer. J Clin Oncol. 31:4140–4147. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang X, Dai W, Kwong DL, Szeto CY, Wong
EH, Ng WT, Lee AW, Ngan RK, Yau CC, Tung SY, et al: Epigenetic
markers for noninvasive early detection of nasopharyngeal carcinoma
by methylation-sensitive high resolution melting. Int J Cancer.
136:E127–E135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Heyn H and Esteller M: DNA methylation
profiling in the clinic: Applications and challenges. Nat Rev
Genet. 13:679–692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Belinsky SA, Klinge DM, Dekker JD, Smith
MW, Bocklage TJ, Gilliland FD, Crowell RE, Karp DD, Stidley CA and
Picchi MA: Gene promoter methylation in plasma and sputum increases
with lung cancer risk. Clin Cancer Res. 11:6505–6511. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Topaloglu O, Hoque MO, Tokumaru Y, Lee J,
Ratovitski E, Sidransky D and Moon CS: Detection of promoter
hypermethylation of multiple genes in the tumor and bronchoalveolar
lavage of patients with lung cancer. Clin Cancer Res. 10:2284–2288.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Geng J, Sun J, Lin Q, Gu J, Zhao Y, Zhang
H, Feng X, He Y, Wang W, Zhou X and Yu J: Methylation status of
NEUROG2 and NID2 improves the diagnosis of stage I NSCLC. Oncol
Lett. 3:901–906. 2012.PubMed/NCBI
|
|
37
|
Schmidt B, Liebenberg V, Dietrich D,
Schlegel T, Kneip C, Seegebarth A, Flemming N, Seemann S, Distler
J, Lewin J, et al: SHOX2 DNA methylation is a biomarker for the
diagnosis of lung cancer based on bronchial aspirates. BMC Cancer.
10:6002010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nikolaidis G, Raji OY, Markopoulou S,
Gosney JR, Bryan J, Warburton C, Walshaw M, Sheard J, Field JK and
Liloglou T: DNA methylation biomarkers offer improved diagnostic
efficiency in lung cancer. Cancer Res. 72:5692–5701. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bearzatto A, Conte D, Frattini M,
Zaffaroni N, Andriani F, Balestra D, Tavecchio L, Daidone MG and
Sozzi G: p16(INK4A) Hypermethylation detected by fluorescent
methylation-specific PCR in plasmas from non-small cell lung
cancer. Clin Cancer Res. 8:3782–3787. 2002.PubMed/NCBI
|
|
40
|
Kurakawa E, Shimamoto T, Utsumi K, Hirano
T, Kato H and Ohyashiki K: Hypermethylation of p16(INK4a) and
p15(INK4b) genes in non-small cell lung cancer. Int J Oncol.
19:277–281. 2001.PubMed/NCBI
|
|
41
|
An Q, Liu Y, Gao Y, Huang J, Fong X, Li L,
Zhang D and Cheng S: Detection of p16 hypermethylation in
circulating plasma DNA of non-small cell lung cancer patients.
Cancer Lett. 188:109–114. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ng CS, Zhang J, Wan S, Lee TW, Arifi AA,
Mok T, Lo DY and Yim AP: Tumor p16M is a possible marker of
advanced stage in non-small cell lung cancer. J Surg Oncol.
79:101–106. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hsu HS, Chen TP, Hung CH, Wen CK, Lin RK,
Lee HC and Wang YC: Characterization of a multiple epigenetic
marker panel for lung cancer detection and risk assessment in
plasma. Cancer. 110:2019–2026. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang YC, Hsu HS, Chen TP and Chen JT:
Molecular diagnostic markers for lung cancer in sputum and plasma.
Ann N Y Acad Sci 1075. 179–184. 2006. View Article : Google Scholar
|
|
45
|
Usadel H, Brabender J, Danenberg KD,
Jerónimo C, Harden S, Engles J, Danenberg PV, Yang S and Sidransky
D: Quantitative adenomatous polyposis coli promoter methylation
analysis in tumor tissue, serum and plasma DNA of patients with
lung cancer. Cancer Res. 62:371–375. 2002.PubMed/NCBI
|
|
46
|
Rykova EY, Skvortsova TE, Laktionov PP,
Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Kolomiets
SA, Sevostianova NV and Vlassov VV: Investigation of tumor-derived
extracellular DNA in blood of cancer patients by
methylation-specific PCR. Nucleosides Nucleotides Nucleic Acids.
23:855–859. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ponomaryova AA, Rykova EY, Cherdyntseva
NV, Skvortsova TE, Dobrodeev AY, Zav'yalov AA, Tuzikov SA, Vlassov
VV and Laktionov PP: RARβ2 gene methylation level in the
circulating DNA from blood of patients with lung cancer. Eur J
Cancer Prev. 20:453–455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ponomaryova AA, Rykova EY, Cherdyntseva
NV, Skvortsova TE, Dobrodeev AY, Zav'yalov AA, Bryzgalov LO,
Tuzikov SA, Vlassov VV and Laktionov PP: Potentialities of
aberrantly methylated circulating DNA for diagnostics and
post-treatment follow-up of lung cancer patients. Lung Cancer.
81:397–403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kneip C, Schmidt B, Seegebarth A,
Weickmann S, Fleischhacker M, Liebenberg V, Field JK and Dietrich
D: SHOX2 DNA methylation is a biomarker for the diagnosis of lung
cancer in plasma. J Thorac Oncol. 6:1632–1638. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chien W and Pei L: A novel binding factor
facilitates nuclear translocation and transcriptional activation
function of the pituitary tumor-transforming gene product. J Biol
Chem. 275:19422–19427. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Heaney AP, Singson R, McCabe CJ, Nelson V,
Nakashima M and Melmed S: Expression of pituitary-tumour
transforming gene in colorectal tumours. Lancet. 355:716–719. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Carvalho L, Yu J, Schwartsmann G, McLeod
HL and Fleshman JW: RNA expression of the molecular signature genes
for metastasis in colorectal cancer. Oncol Rep. 25:1321–1327.
2011.PubMed/NCBI
|
|
53
|
Bernal JA, Luna R, Espina A, Lázaro I,
Ramos-Morales F, Romero F, Arias C, Silva A, Tortolero M and
Pintor-Toro JA: Human securin interacts with p53 and modulates
p53-mediated transcriptional activity and apoptosis. Nat Genet.
32:306–311. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kim DS, Fong J, Read ML and McCabe CJ: The
emerging role of pituitary tumour transforming gene (PTTG) in
endocrine tumourigenesis. Mol Cell Endocrinol. 278:1–6. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Boelaert K, Smith VE, Stratford AL, Kogai
T, Tannahill LA, Watkinson JC, Eggo MC, Franklyn JA and McCabe CJ:
PTTG and PBF repress the human sodium iodide symporter. Oncogene.
26:4344–4356. 2007. View Article : Google Scholar : PubMed/NCBI
|
